Cyrus Khan, MD
Hematology & Oncology · Pittsburgh, PANPI 1558576660
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,532,440 of the $1,913,834 with a category attached, or 80.1%. It is spread thinly across 44 manufacturers, the largest accounting for just 10.4%. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,754 payments — averaging $1091.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$199K
- Genentech USA, Inc.$194K
- Incyte Corporation$190K
- AbbVie$174K
- ADC Therapeutics America, Inc.$169K
- Gilead$124K
- plus $864K from 38 others
Across 333 payments — averaging $7733.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.1M
- Acerta Pharma LLC$326K
- Astrazeneca UK Limited$295K
- Epizyme, Inc.$255K
- Incyte Corporation$192K
- F. Hoffmann-la Roche AG$178K
- plus $218K from 6 others
What the payments were for
- Consulting fees$159,8428%
- Speaking & faculty fees$1,532,44080%
- Travel & lodging$181,3389%
- Food & beverage$39,6652%
- Education$5490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,913,834 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 42 | $627,192 |
| VenclextaVenetoclax | 39 | $395,926 |
| CalquenceAcalabrutinib Maleate | 26 | $376,846 |
| JaypircaPirtobrutinib | 12 | $251,641 |
| BrukinsaZanubrutinib | 23 | $234,385 |
| TasignaNilotinib Hcl | 13 | $57,277 |
| EliquisApixaban | 40 | $23,073 |
| Posaconazole | 11 | $13,872 |
| XareltoRivaroxaban | 13 | $13,841 |
| Acyclovir | 293 | $4,101 |
| Fluconazole | 15 | $917 |
| Oxycodone Hcl | 42 | $740 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $583 |
| Allopurinol | 91 | $520 |
| Prochlorperazine Maleate | 42 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $190,274 | $627,19242 claims |
| AbbVieVenclexta | $174,015 | $395,92639 claims |
| AstraZenecaCalquence | $198,723 | $376,84626 claims |
| Lilly USA, LLCJaypirca | $118,249 | $251,64112 claims |
| Beigene USA, Inc.Brukinsa | $102,004 | $234,38523 claims |
| NovartisTasigna | $1,750 | $57,27713 claims |
| PfizerEliquis | $7,146 | $23,07340 claims |
| Johnson & JohnsonXarelto | $65,088 | $13,84113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Pittsburgh
- Salman FazalPittsburgh$2.3M
- Alexander BarsoukPittsburgh$674K
- Hashem YounesPittsburgh$435K
- Taofeek OwonikokoPittsburgh$346K
- Jason LukePittsburgh$300K
- Ahmad TarhiniPittsburgh$216K
- Diwakar DavarPittsburgh$104K
- Jing Zhou HouPittsburgh$78K
- Vikram GorantlaPittsburgh$62K
- Stanley MarksPittsburgh$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.